Please use this identifier to cite or link to this item: https://doi.org/10.1200/JCO.2012.43.8622
Title: Fibroblast growth factor receptor 1 gene amplification is associated with poor survival and cigarette smoking dosage in patients with resected squamous cell lung cancer
Authors: Kim, H.R.
Kim, D.J.
Kang, D.R.
Lee, J.G.
Lim, S.M.
Lee, C.Y.
Rha, S.Y.
Bae, M.K.
Lee, Y.J.
Kim, S.H.
Ha, S.-J.
Soo, R.A. 
Chung, K.Y.
Kim, J.H.
Lee, J.H.
Shim, H.S.
Cho, B.C.
Issue Date: 20-Feb-2013
Citation: Kim, H.R., Kim, D.J., Kang, D.R., Lee, J.G., Lim, S.M., Lee, C.Y., Rha, S.Y., Bae, M.K., Lee, Y.J., Kim, S.H., Ha, S.-J., Soo, R.A., Chung, K.Y., Kim, J.H., Lee, J.H., Shim, H.S., Cho, B.C. (2013-02-20). Fibroblast growth factor receptor 1 gene amplification is associated with poor survival and cigarette smoking dosage in patients with resected squamous cell lung cancer. Journal of Clinical Oncology 31 (6) : 731-737. ScholarBank@NUS Repository. https://doi.org/10.1200/JCO.2012.43.8622
Abstract: Purpose To investigate the frequency and the prognostic role of fibroblast growth factor receptor 1 (FGFR1) amplification in patients with surgically resected squamous cell carcinoma of the lung (SCCL) and the association between smoking and FGFR1 amplification. Patients and Methods Gene copy number of FGFR1 was investigated in microarrayed tumors from 262 patients with SCCL who had tumor tissue as well as smoking and survival data available. Gene copy number was evaluated by fluorescent in situ hybridization, and an FGFR1-amplified tumor (FGFR1 amp) was prespecified as a tumor with nine or more copies of FGFR1. Results Among 262 patients, the frequency of FGFR1 amp was 13.0%. Patients with FGFR1 amp had significantly shorter disease-free survival (DFS; 26.9 v 94.6 months; P < .001) as well as shorter overall survival (OS; 51.2 v 115.0 months; P = .002) than those without FGFR1 amp. Multivariate modeling confirmed that patients with FGFR1 amp had a significantly greater risk of recurrence and death than those without FGFR1 amp after adjusting for sex, smoking status, pathologic stage, and adjuvant chemotherapy (DFS: adjusted hazard ratio [AHR], 2.24;95%CI, 1.45 to 3.45; P
Source Title: Journal of Clinical Oncology
URI: http://scholarbank.nus.edu.sg/handle/10635/117018
ISSN: 0732183X
DOI: 10.1200/JCO.2012.43.8622
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

137
checked on Oct 22, 2021

WEB OF SCIENCETM
Citations

126
checked on Oct 22, 2021

Page view(s)

102
checked on Oct 14, 2021

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.